AURA Stock Forecast: Aura Biosciences, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Aura Biosciences, Inc. hold a median 12-month price target of $15 — +118.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 61 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Aura Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (81): The share price has been relatively steady.
Issuance (35): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AURA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AURA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +118.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $24 → $18 |
| 29 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $22 → $24 |
| 30 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Nov 2025 | Evercore ISI Group | Reinstates | Outperform | $13 |
| 13 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 May 2025 | HC Wainwright & Co. | Assumes | Buy | $22 |
| 23 May 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 26 Mar 2025 | Citizens Capital Markets | Maintains | Market Outperform | — |
| 26 Mar 2025 | JMP Securities | Maintains | Market Outperform | — |
| 25 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | JMP Securities | Maintains | Market Outperform | — |
| 14 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Oct 2024 | BTIG | Maintains | Buy | — |
| 18 Oct 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Oct 2024 | Scotiabank | Maintains | Sector Outperform | — |
| 13 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Sept 2024 | JMP Securities | Maintains | Market Outperform | — |
| 28 Aug 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 25 July 2024 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AURA.
This page is one stock. Monday covers all of them.
AURA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
AURA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Aura Biosciences, Inc. returned +28.4% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AURA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.5×
- EV / EBITDA
- —
Cheaper than 36% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −61.7%
- Return on assets
- −35.5%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aura Biosciences, Inc. has a market value of $715.0M and an enterprise value of $433.9M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$131.0M.
Free cash flow in the twelve months to 30 June 2026: −$103.4M.
Aura Biosciences, Inc. employs 113 people.
Data provided by Twelve Data
AURA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at AURA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Aura Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about AURA
What is the AURA stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Aura Biosciences, Inc. have a median 12-month price target of $15, with estimates ranging from $12 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AURA stock a buy right now?
Of the 6 analysts covering Aura Biosciences, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aura Biosciences, Inc. 61 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AURA?
As at 21 Nov 2026, Aura Biosciences, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (81 of 100).
Will AURA stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies +118.3% from the last close, and Ticker Nerd's factor model ranks Aura Biosciences, Inc. 61 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AURA stock forecast for 2030?
No analyst covering Aura Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $23 over the next 12 months.
How has AURA stock performed over the past year?
Aura Biosciences, Inc. returned +28.4% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Aura Biosciences, Inc. do?
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function.
About Aura Biosciences, Inc.
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors, with a particular emphasis on ocular cancers. Its lead program centers on belzupacap sarotalocan, a virus-like drug conjugate designed to selectively target cancer cells while preserving healthy tissue and organ function. The company’s platform is built around virus-like particles that deliver therapeutic payloads directly to tumors and support an immune response against cancer. Aura Biosciences is advancing its oncology pipeline across ocular oncology and other related indications, including bladder cancer, using a targeted approach intended for specialist treatment settings. Headquartered in Boston, Massachusetts, Aura Biosciences plays a focused role in the biotechnology market as a developer of novel cancer therapies for hard-to-treat solid tumors.
CEO Ms. Natalie C. Holles · 113 employees · United States · https://www.aurabiosciences.com